Veradermics, Inc. (MANE) announced positive topline results from its Phase 2 clinical trial, Study ‘207,’ for its investigational oral hair loss treatment, VDPHL01, in females with mild-to-moderate pattern hair loss. The study demonstrated significant hair growth and a favorable safety profile, supporting its advancement into later-stage trials.
Key Details
- Drug & Trial: The open-label Phase 2 study evaluated VDPHL01, a proprietary extended-release oral minoxidil, in 28 adult female participants over 6 months.
- Efficacy Results: Participants achieved an average increase in non-vellus hair count of 22.7 hairs/cm² (once-daily dose) and 23.3 hairs/cm² (twice-daily dose). Approximately 90% of patients across both arms reported their hair coverage as 'improved' or 'much improved'.
- Safety Profile: The treatment was generally well-tolerated, with no treatment-related serious adverse events or adverse events of cardiac origin reported. The most common adverse events were hypertrichosis and peripheral edema.
- Next Steps: These positive results support the ongoing registration-directed Phase 2/3 trial (Study ‘306’), with topline data anticipated in the first half of 2027.